Clinical Trial Update: Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on immunotherapy using pluripotent killer-PD-1 cells for advanced hepatocellular carcinoma (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• PIK-PD-1 cells (PIK-PD-1 cells)

Snippet

Sponsor: Second Military Medical University | Conditions: Advanced Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN